Protein Pilfered from Cancer Cells Thwarts Immune Attack

New research in mice reveals why natural killer cells, normally effective at hunting cancer, are sometimes stopped in their tracks.

Written byDan Robitzski
| 3 min read
Artist’s rendering of multiple natural killer cells, colored light pink, attacking a purple tumor cell.
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Natural killer cells, famous for their prowess at wiping out cancer and virus-infected cells, are not always effective, particularly when it comes to fighting tumors. Now, research in mice points to a possible reason: when NK cells “bite off” part of cancer cells’ membranes, they can ingest a serving of protein that renders them useless.

NK cells, also known as large granular lymphocytes, engage tumor cells in a process called trogocytosis, which involves stealing part of their target’s membrane and integrating it into their own. The new study, published today (April 13) in Science Advances, shows in mice with leukemia that this nibble sometimes comes with a side of PD-1, a protein that inhibits NK cell activity, allowing the cancer cell to escape.

When an immune cell such as an NK cell or a T cell encounters PD-1 on the surface of a cancer cell, its activity is subdued. PD-1 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • black and white image of young man in sunglasses with trees in background

    Dan is an award-winning journalist based in Los Angeles who joined The Scientist as a reporter and editor in 2021. Ironically, Dan’s undergraduate degree and brief career in neuroscience inspired him to write about research rather than conduct it, culminating in him earning a master’s degree in science journalism from New York University in 2017. In 2018, an Undark feature Dan and colleagues began at NYU on a questionable drug approval decision at the FDA won first place in the student category of the Association of Health Care Journalists' Awards for Excellence in Health Care Journalism. Now, Dan writes and edits stories on all aspects of the life sciences for the online news desk, and he oversees the “The Literature” and “Modus Operandi” sections of the monthly TS Digest and quarterly print magazine. Read more of his work at danrobitzski.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies